Protocols
9 protocol(s) meet the specified criteria
PI: Grilley-Olson, Juneko
Protocol No.TitleStatus
201404139Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients with Incurable SCCHNOpen
B8011001A Phase 1, Open-Label, Dose Escalation and Expansion Study of PF-06801591 in Patients with Locally Advanced or Metastatic Melanoma, Squamous Cell Head and Neck Cancer, Ovarian Cancer, Sarcoma, or Relapsed or Refractory Classic Hodgkin Lymphoma or Other Solid TumorsOpen
D6410C00001A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally as a Single Agent in Subjects with Solid Tumors or CTCL and in Combination with Durvalumab and Palliative Radiation in Subjects with Solid TumorsOpen
EAY131-CIRBMolecular Analysis of Therapy Choice (MATCH)Open
LOXO-TRK-15002A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive TumorsOpen
ML28897PRO/02My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to one of these Agents.Open
NC-6004-004AA Phase 1b/2 Dose Escalation and Expansion Trial of NC-6004 (Nanoparticle Cisplatin) plus Gemcitabine in Patients with Advanced Solid Tumors or Non-Small Cell Lung Cancer, Biliary Tract, and Bladder CancerOpen
NC-6004-008Phase I/II Clinical Trial of NC-6004 in Combination with 5-FU and Cetuximab as First-line Treatment in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of The Head and NeckOpen
SGNS40-001SGNS40-001 – A phase 1, open-label, dose-escalation study of SEA-CD40 in adult patients with advanced malignanciesOpen